BRPI0515033B1 - Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero - Google Patents
Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero Download PDFInfo
- Publication number
- BRPI0515033B1 BRPI0515033B1 BRPI0515033-7A BRPI0515033A BRPI0515033B1 BR PI0515033 B1 BRPI0515033 B1 BR PI0515033B1 BR PI0515033 A BRPI0515033 A BR PI0515033A BR PI0515033 B1 BRPI0515033 B1 BR PI0515033B1
- Authority
- BR
- Brazil
- Prior art keywords
- mixture
- solution
- polypeptides
- acid
- tyrosine
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 125
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 125
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 125
- 239000000203 mixture Substances 0.000 title claims abstract description 109
- 238000000034 method Methods 0.000 title claims abstract description 62
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims description 100
- 229960003776 glatiramer acetate Drugs 0.000 title claims description 90
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims description 86
- 125000004044 trifluoroacetyl group Chemical class FC(C(=O)*)(F)F 0.000 title claims description 45
- 238000004519 manufacturing process Methods 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 18
- 239000012535 impurity Substances 0.000 claims abstract description 57
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 56
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 47
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 45
- 235000002374 tyrosine Nutrition 0.000 claims abstract description 45
- 235000004279 alanine Nutrition 0.000 claims abstract description 42
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 40
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 37
- 150000003668 tyrosines Chemical class 0.000 claims abstract description 34
- 150000001413 amino acids Chemical group 0.000 claims abstract description 33
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 30
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 28
- 239000004220 glutamic acid Substances 0.000 claims abstract description 28
- 239000004472 Lysine Substances 0.000 claims abstract description 25
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000018977 lysine Nutrition 0.000 claims abstract description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 348
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 97
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 57
- 229910052794 bromium Inorganic materials 0.000 claims description 55
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 53
- KNCHTBNNSQSLRV-YFKPBYRVSA-N (2s)-6-amino-2-[(2,2,2-trifluoroacetyl)amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)C(F)(F)F KNCHTBNNSQSLRV-YFKPBYRVSA-N 0.000 claims description 24
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 24
- RLRYVSYUAHQYLS-QMMMGPOBSA-N (2s)-2-(bromoamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](NBr)CC1=CC=C(O)C=C1 RLRYVSYUAHQYLS-QMMMGPOBSA-N 0.000 claims description 19
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- -1 Y-benzyl glutamate Chemical compound 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 10
- 239000012488 sample solution Substances 0.000 claims description 10
- 238000010511 deprotection reaction Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000004364 calculation method Methods 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims 3
- 241001550224 Apha Species 0.000 claims 2
- 239000000243 solution Substances 0.000 description 92
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 38
- 229960004441 tyrosine Drugs 0.000 description 37
- 229960003767 alanine Drugs 0.000 description 35
- 229960002989 glutamic acid Drugs 0.000 description 24
- 229960003646 lysine Drugs 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000019766 L-Lysine Nutrition 0.000 description 6
- 229940038717 copaxone Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229940042385 glatiramer Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052755 nonmetal Inorganic materials 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- CLBRCZAHAHECKY-UHFFFAOYSA-N [Co].[Pt] Chemical compound [Co].[Pt] CLBRCZAHAHECKY-UHFFFAOYSA-N 0.000 description 3
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229910020437 K2PtCl6 Inorganic materials 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UBPJIGYYLTZEDD-UHFFFAOYSA-N 2-amino-3-(2-bromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1Br UBPJIGYYLTZEDD-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical class OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- HGWOSUKIFQMEIF-ZETCQYMHSA-N 3-bromo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Br)=C1 HGWOSUKIFQMEIF-ZETCQYMHSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- HINSMVRGSUGPBM-UHFFFAOYSA-N acetyl 2,2,2-trifluoroacetate Chemical compound CC(=O)OC(=O)C(F)(F)F HINSMVRGSUGPBM-UHFFFAOYSA-N 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical group C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60884304P | 2004-09-09 | 2004-09-09 | |
| US60/608,843 | 2004-09-09 | ||
| PCT/US2005/032395 WO2006029393A2 (en) | 2004-09-09 | 2005-09-09 | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0515033A BRPI0515033A (pt) | 2008-07-01 |
| BRPI0515033A8 BRPI0515033A8 (pt) | 2019-01-22 |
| BRPI0515033B1 true BRPI0515033B1 (pt) | 2021-05-25 |
Family
ID=36037047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0515033-7A BRPI0515033B1 (pt) | 2004-09-09 | 2005-09-09 | Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7495072B2 (OSRAM) |
| EP (3) | EP1799703B1 (OSRAM) |
| JP (1) | JP5149008B2 (OSRAM) |
| KR (1) | KR101317131B1 (OSRAM) |
| CN (1) | CN101166754B (OSRAM) |
| AT (2) | ATE536363T1 (OSRAM) |
| AU (1) | AU2005282249B2 (OSRAM) |
| BR (1) | BRPI0515033B1 (OSRAM) |
| CA (1) | CA2579656C (OSRAM) |
| CY (1) | CY1110280T1 (OSRAM) |
| DE (1) | DE602005018800D1 (OSRAM) |
| DK (3) | DK1799703T3 (OSRAM) |
| ES (3) | ES2451006T3 (OSRAM) |
| HR (3) | HRP20100164T1 (OSRAM) |
| IL (2) | IL181596A (OSRAM) |
| IS (1) | IS8622A (OSRAM) |
| MX (1) | MX2007002760A (OSRAM) |
| NO (1) | NO20071632L (OSRAM) |
| NZ (1) | NZ554018A (OSRAM) |
| PL (3) | PL2361924T3 (OSRAM) |
| PT (3) | PT1799703E (OSRAM) |
| RS (3) | RS53248B (OSRAM) |
| RU (1) | RU2388764C2 (OSRAM) |
| SI (3) | SI2361924T1 (OSRAM) |
| UA (1) | UA91029C2 (OSRAM) |
| WO (1) | WO2006029393A2 (OSRAM) |
| ZA (1) | ZA200702591B (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE60237170D1 (de) * | 2001-12-04 | 2010-09-09 | Teva Pharma | Verfahren zur messung der wirkstärke von glatirameracetat |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| MX2007002760A (es) * | 2004-09-09 | 2007-05-18 | Teva Pharma | Procedimiento para la preparacion de mezclas de polipeptidos y utilizando acido bromhidrico purificado. |
| WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US8324641B2 (en) * | 2007-06-29 | 2012-12-04 | Ledengin, Inc. | Matrix material including an embedded dispersion of beads for a light-emitting device |
| ES2331015T3 (es) * | 2004-10-29 | 2009-12-18 | Sandoz Ag | Proceso para la preparacion de un glatiramero. |
| NZ556156A (en) * | 2005-02-02 | 2010-03-26 | Teva Pharma | Process for producing acetate salts of polypeptides using hydrogenolysis |
| PT1848415E (pt) * | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
| EP1891233A4 (en) * | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| WO2009017775A2 (en) * | 2007-08-02 | 2009-02-05 | Scinopharm Taiwan Ltd. | Process for the preparation of a polypeptide |
| AU2008330093A1 (en) * | 2007-11-28 | 2009-06-04 | Yeda Research And Development Co., Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| EP2277050B2 (en) | 2008-04-16 | 2022-09-28 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
| KR20110059606A (ko) * | 2008-08-07 | 2011-06-02 | 시노팜 타이완 리미티드 | 글라티라머 아세테이트의 합성 |
| WO2010017075A1 (en) * | 2008-08-07 | 2010-02-11 | Sigma-Aldrich Co. | Preparation of low molecular weight polylysine and polyornithine in high yield |
| US8859489B2 (en) * | 2009-04-03 | 2014-10-14 | Momenta Pharmaceuticals, Inc. | Water-mediated control of depolymerization step of glatiramer acetate synthesis |
| UA103699C2 (ru) | 2009-08-20 | 2013-11-11 | Еда Рисёрч Энд Девелопмент Ко., Лтд. | Терапия глатирамера ацетатом с низкой частотой |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EP2563804A4 (en) * | 2010-04-27 | 2014-09-17 | Reddys Lab Ltd Dr | PREPARATION OF POLYPEPTIDES AND THEIR SALTS |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| US8788046B2 (en) | 2010-11-11 | 2014-07-22 | Spr Therapeutics, Llc | Systems and methods for the treatment of pain through neural fiber stimulation |
| CA2827275A1 (en) * | 2011-02-14 | 2012-09-20 | Usv Limited | Copolymer-1, process for preparation and analytical methods thereof |
| JP5701103B2 (ja) * | 2011-03-02 | 2015-04-15 | 昭和シェル石油株式会社 | 潤滑油のための消泡剤組成物及びそれを用いた消泡方法 |
| WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
| WO2013009864A1 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Structure assessment of heterogeneous polypeptide mixtures |
| WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
| US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| CA2851510A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| CN102717992A (zh) * | 2012-05-30 | 2012-10-10 | 苏州市旭洋工业搪瓷厂 | 一种搪玻璃溴素贮罐 |
| CN102718963B (zh) * | 2012-06-19 | 2014-10-15 | 深圳翰宇药业股份有限公司 | 聚合物多肽的制备方法 |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2015066515A1 (en) | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| CN104844697B (zh) | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| US12370233B2 (en) | 2016-08-31 | 2025-07-29 | Mapi Pharma Ltd. | Depot systems comprising glatiramer acetate |
| WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| US20190202984A1 (en) * | 2018-01-03 | 2019-07-04 | Kinbio Ltd. | Process of preparing glatiramer acetate |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846550A (en) * | 1971-01-21 | 1974-11-05 | H Akrongold | Cosmetic skin powder containing urea |
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| JPS54119499A (en) * | 1978-03-09 | 1979-09-17 | Shionogi & Co Ltd | Triazolobenzodiazepin derivative |
| JPS6053535A (ja) * | 1983-09-02 | 1985-03-27 | Nitto Boseki Co Ltd | 規則性ポリアミノ酸樹脂の製造方法 |
| SU1182051A1 (ru) | 1984-04-28 | 1985-09-30 | Таджикский государственный университет им.В.И.Ленина | Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина |
| AU596986B2 (en) | 1985-06-18 | 1990-05-24 | Emory University | Biologically-active copolymers |
| DD257174A3 (de) | 1985-12-20 | 1988-06-08 | Ve Forschungszentrum Biotechno | Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease |
| SU1469826A1 (ru) | 1986-05-30 | 1995-11-20 | Институт Высокомолекулярных Соединений Ан Ссср | Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения |
| SU1690368A1 (ru) | 1989-07-20 | 1995-08-20 | Институт Высокомолекулярных Соединений Ан Ссср | Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения |
| DE3930733A1 (de) | 1989-09-14 | 1991-03-28 | Roehm Gmbh | Verfahren zur herstellung eines komplexierten arzneimittels |
| USH1312H (en) * | 1992-05-28 | 1994-05-03 | Cytogen Corporation | Method for the preparation of gyk-dtpa |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| RU2161489C2 (ru) * | 1994-05-24 | 2001-01-10 | Еда Рисерч энд Дивелопмент Ко. Лтд. | Усовершенствованный сополимер-1 в сополимерных композициях |
| US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| FR2750423B1 (fr) | 1996-06-28 | 1998-08-14 | Rhone Poulenc Chimie | Procede d'hydrogenation asymetrique d'un compose cetonique |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| KR20010015639A (ko) | 1997-09-30 | 2001-02-26 | 스즈키 다다시 | 술포닐 유도체 |
| US5872122A (en) * | 1997-10-16 | 1999-02-16 | Monsanto Company | Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation |
| US5965047A (en) | 1997-10-24 | 1999-10-12 | Steag Ast | Rapid thermal processing (RTP) system with rotating substrate |
| GB9724627D0 (en) | 1997-11-20 | 1998-01-21 | Genencor Int Bv | Gram positive microorganism formate pathway |
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
| US6114649A (en) | 1999-07-13 | 2000-09-05 | Duran Technologies Inc. | Anode electrode for plasmatron structure |
| EP1250450A2 (en) | 1999-09-03 | 2002-10-23 | University of Iowa Research Foundation Inc. | Quorum sensing signaling in bacteria |
| DE19944003C1 (de) | 1999-09-14 | 2001-03-22 | Baumeister & Ostler Gmbh Co | Faltbare Trenneinrichtung |
| PT1248643E (pt) | 2000-01-20 | 2005-10-31 | Yeda Res & Dev | Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora |
| MXPA02008023A (es) | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| ZA200206457B (en) * | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| EP1294390B1 (en) | 2000-06-07 | 2006-01-04 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| JP3698984B2 (ja) | 2000-11-10 | 2005-09-21 | ヤマウチ株式会社 | シュープレス用ベルト |
| EP1351686A2 (en) * | 2000-11-20 | 2003-10-15 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| JP3661935B2 (ja) | 2001-06-20 | 2005-06-22 | ソニー株式会社 | 情報処理装置および方法、記録媒体、並びにプログラム |
| DE60237170D1 (de) * | 2001-12-04 | 2010-09-09 | Teva Pharma | Verfahren zur messung der wirkstärke von glatirameracetat |
| WO2004036172A2 (en) | 2002-05-09 | 2004-04-29 | Dennis Farwell | Bioweapon-detecting fibrous-network products and methods for making same |
| CA2411786C (en) * | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
| AU2003283152A1 (en) * | 2002-11-13 | 2004-06-03 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| DE10353960B4 (de) | 2003-10-16 | 2006-03-23 | Vertilas Gmbh | Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter |
| WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| MX2007002760A (es) * | 2004-09-09 | 2007-05-18 | Teva Pharma | Procedimiento para la preparacion de mezclas de polipeptidos y utilizando acido bromhidrico purificado. |
| NZ556156A (en) * | 2005-02-02 | 2010-03-26 | Teva Pharma | Process for producing acetate salts of polypeptides using hydrogenolysis |
| EP1891233A4 (en) * | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| WO2007072865A1 (ja) | 2005-12-22 | 2007-06-28 | Pioneer Corporation | 施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体 |
-
2005
- 2005-09-09 MX MX2007002760A patent/MX2007002760A/es active IP Right Grant
- 2005-09-09 PT PT05791236T patent/PT1799703E/pt unknown
- 2005-09-09 KR KR1020077007738A patent/KR101317131B1/ko not_active Expired - Lifetime
- 2005-09-09 AT AT10150124T patent/ATE536363T1/de active
- 2005-09-09 EP EP05791236A patent/EP1799703B1/en not_active Revoked
- 2005-09-09 PT PT10150124T patent/PT2177528E/pt unknown
- 2005-09-09 CN CN200580033851.5A patent/CN101166754B/zh not_active Expired - Lifetime
- 2005-09-09 DK DK05791236.2T patent/DK1799703T3/da active
- 2005-09-09 RS RS20140097A patent/RS53248B/sr unknown
- 2005-09-09 DK DK10150124.5T patent/DK2177528T3/da active
- 2005-09-09 SI SI200531830T patent/SI2361924T1/sl unknown
- 2005-09-09 RU RU2007112956/04A patent/RU2388764C2/ru active
- 2005-09-09 BR BRPI0515033-7A patent/BRPI0515033B1/pt not_active IP Right Cessation
- 2005-09-09 ZA ZA200702591A patent/ZA200702591B/xx unknown
- 2005-09-09 PL PL10194363T patent/PL2361924T3/pl unknown
- 2005-09-09 WO PCT/US2005/032395 patent/WO2006029393A2/en not_active Ceased
- 2005-09-09 PL PL05791236T patent/PL1799703T3/pl unknown
- 2005-09-09 DK DK10194363.7T patent/DK2361924T3/en active
- 2005-09-09 RS RS20120091A patent/RS52265B/sr unknown
- 2005-09-09 AT AT05791236T patent/ATE454396T1/de active
- 2005-09-09 ES ES10194363.7T patent/ES2451006T3/es not_active Expired - Lifetime
- 2005-09-09 EP EP10150124A patent/EP2177528B1/en not_active Revoked
- 2005-09-09 CA CA2579656A patent/CA2579656C/en not_active Expired - Lifetime
- 2005-09-09 HR HR20100164T patent/HRP20100164T1/hr unknown
- 2005-09-09 DE DE602005018800T patent/DE602005018800D1/de not_active Expired - Lifetime
- 2005-09-09 UA UAA200703838A patent/UA91029C2/uk unknown
- 2005-09-09 ES ES05791236T patent/ES2338138T3/es not_active Expired - Lifetime
- 2005-09-09 JP JP2007531423A patent/JP5149008B2/ja not_active Expired - Fee Related
- 2005-09-09 PT PT101943637T patent/PT2361924E/pt unknown
- 2005-09-09 ES ES10150124T patent/ES2382298T3/es not_active Expired - Lifetime
- 2005-09-09 EP EP10194363.7A patent/EP2361924B1/en not_active Revoked
- 2005-09-09 AU AU2005282249A patent/AU2005282249B2/en not_active Expired
- 2005-09-09 NZ NZ554018A patent/NZ554018A/en not_active IP Right Cessation
- 2005-09-09 RS RSP-2010/0114A patent/RS51257B/sr unknown
- 2005-09-09 PL PL10150124T patent/PL2177528T3/pl unknown
- 2005-09-09 SI SI200530934T patent/SI1799703T1/sl unknown
- 2005-09-09 SI SI200531482T patent/SI2177528T1/sl unknown
- 2005-09-09 US US11/223,072 patent/US7495072B2/en not_active Expired - Lifetime
-
2006
- 2006-09-27 US US11/529,668 patent/US20070021324A1/en not_active Abandoned
-
2007
- 2007-02-27 IL IL181596A patent/IL181596A/en active IP Right Grant
- 2007-03-16 IS IS8622A patent/IS8622A/is unknown
- 2007-03-28 NO NO20071632A patent/NO20071632L/no not_active Application Discontinuation
-
2010
- 2010-03-31 CY CY20101100308T patent/CY1110280T1/el unknown
-
2012
- 2012-03-02 HR HRP20120209TT patent/HRP20120209T1/hr unknown
-
2014
- 2014-03-10 HR HRP20140216TT patent/HRP20140216T1/hr unknown
-
2015
- 2015-09-17 IL IL241702A patent/IL241702A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0515033B1 (pt) | Processo para a obtenção de uma mistura de polipeptídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica e para a produção de acetato de glatirâmero | |
| Szabo et al. | A zinc finger‐like domain of the molecular chaperone DnaJ is involved in binding to denatured protein substrates. | |
| Abu-Hamdiyyah et al. | Transfer enthalpies and entropies of amino acids from water to urea solutions | |
| HK1140775B (en) | Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid | |
| HK1100780B (en) | Process for preparation of mixtures of polypeptides using purified hydrobromic acid | |
| HK1156637B (en) | Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid | |
| JP7568245B2 (ja) | 生化学医療診断キット | |
| EP4302086A1 (en) | Biochemical medical diagnostic kit | |
| OA21368A (en) | Biochemical medical diagnostic kit. | |
| JPH07239332A (ja) | リムルス試薬およびリムルス試薬反応性物質の測定法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B17A | Notification of administrative nullity (patentee has 60 days time to reply to this notification) |
Free format text: REQUERENTE DA NULIDADE: CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA - 870210109409 - 25/11/2021 |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2791, DE 02/07/2024, EM VIRTUDE DO DESPACHO PUBLICADO NA RPI 2727, DE 11/04/2023, ANULANDO O PRIVILEGIO. |